Artificial Intelligence
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
– Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 –
– Strong cash position of $266 million supports clinical development and manufacturing expansion into 2H 2024 –
LONDON, March 01, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2021, and recent business highlights.
“In 2021, we generated clinical data demonstrating the unique ability of our T cell platform to detect, quantify and track our clonal neoantigen-reactive T cells, or cNeT, in vivo, giving us the analytical platform to elucidate the mechanism of action of our cNeT product. cNeT dose is now being used in our clinical trials as a release parameter, highlighting our differentiated potential to develop potency assays that we believe are essential for the successful development and regulatory approval of TIL-based therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. “In the year ahead, we will build on the important learnings from our first cohort of patients by evaluating higher doses of our tumor-targeting cNeT therapies alone and in combination with a checkpoint inhibitor. We look forward to clinical readouts in our CHIRON and THETIS trials for non-small cell lung cancer and melanoma, respectively, including 6-week clinical activity and engraftment data in the second half of 2022.
Our unique ability to prospectively target and track clonal neoantigens is possible through PELEUS™, our proprietary bioinformatics platform. PELEUS was built on an advanced statistical framework to differentiate clonal from subclonal mutations and is further enhanced using Artificial Intelligence in a range of applications, including neoantigen prioritization. PELEUS is validated through our exclusive access to the landmark TRACERx clinical study of tumor evolution, which provides the extensive longitudinal sequencing data of over 3,200 tumor samples that have been collected over five years from over 795 patients. The detailed genomic analysis from PELEUS allows us to identify the unique clonal neoantigens of each patient. These clonal neoantigens are protein markers that are present on all of an individual’s cancer cells but are absent from healthy tissue, making them ideal cancer targets. With this information, our VELOS manufacturing process uses the natural biology of dendritic cell antigen presentation to select and expand the T cells that are able to recognize the clonal neoantigen targets present in a patient’s tumor. With these powerful, proprietary tools and our forthcoming clinical data, we are well-positioned to advance our precision T cell therapy.
We expect to continue to expand our global footprint with increased manufacturing capacity in the U.K., continued addition of clinical sites, and establishment of our U.S. headquarters in Philadelphia which will house our first U.S. R&D facility. With the capital raised in our successful IPO in April 2021, we have $266 million in cash and cash equivalents to support the clinical development of our cNeT therapy in melanoma, non-small cell lung cancer, head and neck cancer, and other indications into the second half of 2024.”
2021 Business Highlights and Recent Updates
- Established a U.S. headquarters in Philadelphia, PA which will include an R&D facility
- Strengthened the Scientific Advisory Board and Board of Directors with appointments of Alena Gros, Ph.D. and Ben Creelan, M.D. (Press Release, February 2022) and Julie O’Neill and Markwin Velders, Ph.D. (Press Release, May 2021)
- Added to the NASDAQ Biotechnology Index (Press Release, December 2021) and the ICE Biotechnology Index
- Presented data at the ESMO I-O Congress on VELOS Process 2 manufacturing (Press Release, December 2021) highlighting a median dose of 200m cNeT in pre-clinical GMP runs, more than a 10-fold increase over the median dose manufactured with Process 1
- Presented data at AACR (Press Release, April 2021) and SITC Annual Meetings (Press Release, November 2021) showing the detection, quantification and tracking of patient-specific cNeT
- Received regulatory approval for the use of VELOS Process 2 manufacturing in the UK, France, Germany, and Spain in November 2021
- Presented details of the Material Acquisition Platform (MAP) at the 2021 ESGCT Congress, supporting the potential use of cNeT in a broad range of solid tumor indications (Press Release, October 2021)
- Expanded the Company’s intellectual property estate, including the grant of US and European patents supporting the approach of targeting clonal neoantigens that are identified with the proprietary PELEUSTM bioinformatics platform (Press Release, August 2021)
- Raised gross proceeds of $175.5 million in an initial public offering (Press Release, April 2021)
Financial Highlights
- Cash and cash equivalents: Cash and cash equivalents were $266.3 million as of December 31, 2021, as compared to $177.8 million as of December 31, 2020. The Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials
- Research and development (R&D) expenses: R&D expenses were $11.8 million for the fourth quarter ended December 31, 2021, an increase of $2.8 million compared to $9.0 million for the fourth quarter ended December 30, 2020. R&D expenses were $42.2 million for the year ended December 31, 2021, an increase of $19.6 million compared to $22.6 million for the year ended December 31, 2020. The increase was primarily driven by increased activity related to our ongoing clinical trials and overall R&D
- General and administrative (G&A) expenses: G&A expenses were $6.7 million for the fourth quarter ended December 31, 2021, an increase of $2.7 million compared to $4.0 million for December 31, 2020. G&A expenses were $22.0 million for the year ended December 31, 2021, an increase of $10.9 million compared to the $11.1 million for the year ended December 31, 2020. The increase was primarily driven by fees associated with the Company’s public company obligations, and an increase in headcount and related personnel costs
- Net loss: Net loss for the fourth quarter ended December 31, 2021 was $18.2 million or $0.45 per share compared to $12.9 million or $9.32 per share for the fourth quarter ended December 31, 2020. Net loss for the year ended December 31, 2021 was $61.1 million or $2.13 per share compared to $33.2 million or $31.14 per share for the year ended December 31, 2020. The decrease in loss per share is due in part to the increased number of shares following the conversion and issuance of shares from the IPO
2022 Milestones and Upcoming Events
- Patient Dosing: Dose first patients with higher dose (Process 2) cNeT monotherapy and cNeT in combination with a PD-1 inhibitor in 2Q 2022
- Higher-dose Monotherapy: Report additional patient data from higher-dose cohort (Process 2) of cNeT monotherapy for the treatment of NSCLC and melanoma in 2H 2022
- cNeT Combination: Report initial patient data from cNeT in combination with a PD-1 inhibitor for the treatment of melanoma in 2H 2022
- Manufacturing Expansion: Increase manufacturing capacity in the United Kingdom with GMP licensure of the Cell & Gene Therapy Catapult facility in 2Q 2022
- Tumor Archiving Program: Initiate program in 1H 2022
Achilles will present at the upcoming conferences. Additional details will be available in the Events & Presentations section of the Company’s website:
- BioCapital Europe, Organized by LSP: March 10, 2022
- Oppenheimer 32nd Annual Healthcare Conference: March 15 – 16, 2022
- Immuno-Oncology 360°: March 16 – 18, 2022
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Forward-Looking Statements
This press release contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contacts:
Investors:
Achilles Therapeutics
Lee M. Stern, VP, IR & External Communications
[email protected]
LifeSci Advisors
John Mullaly
[email protected]
Media:
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virdi, Melissa Gardiner
+44 (0) 203 709 5000
[email protected]
ACHILLES THERAPEUTICS PLC
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
| December 31, | ||||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 266,319 | $ | 177,849 | |||||
| Prepaid expenses and other current assets | 18,430 | 9,948 | ||||||
| Total current assets | 284,749 | 187,797 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 17,743 | 13,369 | ||||||
| Operating lease right of use assets | 11,048 | 14,740 | ||||||
| Deferred tax assets | 26 | 4 | ||||||
| Restricted cash | 33 | — | ||||||
| Other assets | 3,507 | 3,008 | ||||||
| Total non-current assets | 32,357 | 31,121 | ||||||
| TOTAL ASSETS | $ | 317,106 | $ | 218,918 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,722 | $ | 6,314 | ||||
| Income taxes payable | — | 7 | ||||||
| Accrued expenses and other liabilities | 10,906 | 6,590 | ||||||
| Operating lease liabilities—current | 4,482 | 3,712 | ||||||
| Total current liabilities | 19,110 | 16,623 | ||||||
| Non-current liabilities: | ||||||||
| Operating lease liabilities-non-current | 7,777 | 12,271 | ||||||
| Other long-term liability | 691 | 652 | ||||||
| Total non-current liabilities | 8,468 | 12,923 | ||||||
| Total liabilities | 27,578 | 29,546 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
| Ordinary shares, £0.001 par value; 40,603,489 and 4,389,920 shares authorized, issued and outstanding at December 31,2021 and 2020, respectively |
54 | 6 | ||||||
| Deferred shares, £92,451.851 par value, one share authorized, issued and outstanding at December 31, 2021; Deferred shares, £0.001 par value; 30,521 shares issued and outstanding at December 31,2020 |
128 | — | ||||||
| Convertible preferred shares, £0.001 par value; no shares authorized, issued and outstanding as of December 31, 2021; 104,854,673 shares authorized, issued and outstanding at December 31, 2020 |
— | 134 | ||||||
| Additional paid in capital | 401,821 | 234,922 | ||||||
| Accumulated other comprehensive income | 6,636 | 12,322 | ||||||
| Accumulated deficit | (119,111 | ) | (58,012 | ) | ||||
| Total shareholders’ equity | 289,528 | 189,372 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 317,106 | $ | 218,918 | ||||
ACHILLES THERAPEUTICS PLC
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development | $ | 11,807 | $ | 8,961 | $ | 42,224 | $ | 22,629 | ||||||||
| General and administrative | 6,653 | 3,958 | 21,971 | 11,098 | ||||||||||||
| Total operating expenses | 18,460 | 12,919 | 64,195 | 33,727 | ||||||||||||
| LOSS FROM OPERATIONS: | (18,460 | ) | (12,919 | ) | (64,195 | ) | (33,727 | ) | ||||||||
| OTHER INCOME (EXPENSE), NET: | ||||||||||||||||
| Other income (expense) | 226 | 2 | 3,133 | 531 | ||||||||||||
| Total other income (expense), net | 226 | 2 | 3,133 | 531 | ||||||||||||
| Loss before income taxes | (18,234 | ) | (12,917 | ) | (61,062 | ) | (33,196 | ) | ||||||||
| Benefit (provision) for income taxes | 4 | (3 | ) | (37 | ) | (3 | ) | |||||||||
| Net loss | (18,230 | ) | (12,920 | ) | (61,099 | ) | (33,199 | ) | ||||||||
| Other comprehensive (loss) income: | ||||||||||||||||
| Foreign exchange translation adjustment | 886 | 7,301 | (5,686 | ) | 4,213 | |||||||||||
| Comprehensive loss | $ | (17,344 | ) | $ | (5,619 | ) | $ | (66,785 | ) | $ | (28,986 | ) | ||||
| Net loss per share attributable to ordinary shareholders—basic and diluted | $ | (0.45 | ) | $ | (9.32 | ) | $ | (2.13 | ) | $ | (31.14 | ) | ||||
| Weighted average ordinary shares outstanding—basic and diluted | 40,245,543 | 1,386,221 | 28,654,760 | 1,066,208 | ||||||||||||
Artificial Intelligence
Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
LAGOS, Nigeria, June 2, 2024 /PRNewswire/ — The Federal Government through the Nigeria Data Protection Commission (NDPC) has granted a licence to the Institute of Information Management (IIM) to conduct examinations and certify data protection professionals for global competitiveness.
The National Commissioner of NDPC, Dr. Vincent Olatunji, who said this on Monday while presenting licence to IIM in Abuja, said granting of the licence was part of the commission’s measures to implement Executive Order 003 and 005.
Olatunji added that certifying data protection professionals in the country would reduce capital flight, create over 500,000 jobs in the sector, and encourage more people to be certified.
Promoting local content
While a few Nigerians with expertise in data protection had their training and certification abroad, Olatunji said having an institute to train and certify Nigerians locally would boost local content in the sector.
“We are trying to ensure the implementation of Executive Orders 003 and 005 to promote local content in Nigeria. Most of us who are certified data protection officers have international certifications; we paid some dollars to write exams as well as maintain the certificates. We are trying to domesticate this in Nigeria by having a national certification process” Olatunji said.
The NDPC National Commissioner said that with the size of Nigeria’s population, the country needs over 500,000 certified data protection officers. And if prospective candidates are to pay for the certifying examination in dollars, it will lead to capital flight.
Expansion to Africa
Olatunji also said that the commission is considering adopting the licensing across Africa. According to him, the Commission is working towards having a pan-African initiative, whereby data professionals have the national certification that is being offered in Nigeria and can also practice in any part of Africa.
“It is a way of creating jobs for our people, reducing capital flight, and developing global human capital in the data protection ecosystem” Olatunji said. He explained the Commission have also gone further to develop the training model which is unique to the organization and will be used by trainers in Nigeria.
He added that the licensing would also create jobs for already licensed Data Protection Compliance Organisations (DPCOs), who would be accredited to train prospective professionals to sit for data protection examinations. According to him, the national data protection certification will be a historic legacy that will transcend administrations and meet global standards.
Speaking on the licence, the President of the Institute of Information Management, Dr. Oyedokun Oyewole, recalled that the certification process commenced in 2021.
He said the licence would bridge the gap in the data protection ecosystem. Oyewole assured Nigerians of the institute’s commitment to be the best in the education system of data protection in the country.
Contact
Celestine AchiCell: +234-08099997175Email: [email protected]
Photo – https://mma.prnewswire.com/media/2427759/IIM.jpg
View original content:https://www.prnewswire.co.uk/news-releases/federal-government-authorizes-institute-of-information-management-to-certify-data-protection-professionals-in-nigeria-302161242.html
USA News Group Commentary Issued on behalf of Avant Technologies Inc.
VANCOUVER, May 31, 2024 /PRNewswire/ — USA News Group – With the artificial intelligence (AI) revolution fully underway, the importance and security of the data centers that power the new technology is surging. The role and preservation of these data centers is generating multiple calls for them and their power sources to be recognized as a matter of national security. Former Google CEO Eric Schmidt went so far as to predict that AI data centers will one day be “on military bases surrounded by machine guns,” as stated in an interview with Noema Magazine. According to analysts at Dell’Oro Group, data center spending is forecast to grow at an astounding 18% CAGR over the next 5 years. Behind the scenes, tech companies are working tirelessly to provide new developments that will make this transition go smoother, including from Avant Technologies Inc. (OTCQB: AVAI), Equinix, Inc. (NASDAQ: EQIX), Vertiv Holdings Co (NYSE: VRT), Iron Mountain Incorporated (NYSE: IRM), and Snowflake Inc. (NYSE: SNOW).
At the forefront of generative AI innovation, Avant Technologies Inc. (OTCQB: AVAI) has been perfecting its flagship product, Avant AITM. The cutting-edge AI system is praised for its machine and deep learning capabilities, making it suitable for a wide range of industries and applications. To explore future possibilities for its AI data center cloud infrastructure, Avant recently engaged Wired4Tech, a highly regarded AI infrastructure consulting firm.
“We are excited to engage Wired4Tech to benchmark the performance of an innovative, next-generation AI server,” said William Hisey, CEO of Avant Technologies. “By conducting rigorous benchmark testing of this promising server technology, we expect to validate its expected performance and cost-saving benefits.”
As part of the new agreement, Wired4Tech will carry out detailed performance benchmarking for Avant. This will include evaluating key metrics such as response time, throughput, CPU and memory usage, disk I/O, network latency, and error rates. A special focus will be placed on response time, analyzing how quickly the server responds to different actions to provide insights into its overall responsiveness.
Avant considers these metrics to be critical for evaluating the server’s ability to handle complex AI tasks both effectively and dependably. Furthermore, Wired4Tech will examine the server’s power usage and identify possible cost-saving opportunities.
Prior to this update, Avant Technologies revealed a bold initiative to create groundbreaking, proprietary AI software aimed at improving its next-generation data centers. Additionally, the company intends to implement AI-driven Zero Trust Architecture (ZTA) throughout its data center operations. The AvantAI™ platform has also been upgraded to feature intelligent, proactive monitoring and management capabilities for data centers.
Digital infrastructure company Equinix, Inc. (NASDAQ: EQIX) recently announced the availability of Dell PowerStore on its Equinix Metal, a new, enterprise-grade Storage as a Service (STaaS) solution. The new availability enables enterprises to unlock multicloud strategies with enhanced performance, security and control, by marrying Equinix’s cloud adjacency and Dell’s leading storage solutions.
“Businesses need storage solutions that allow them to be more agile and get the most out of their hybrid multicloud architectures,” said Merrie Williamson, Chief Customer and Revenue Officer at Equinix. “By combining the powerful capabilities of Dell PowerStore with Equinix’s global platform, we are giving them the low-latency, high-performance connectivity they require without sacrificing on security or breaking their budget.”
The Dell PowerStore on Equinix Metal service offers businesses an easy way to manage and deploy their storage, computing, and networking needs worldwide. This service helps reduce the complexity and costs of running IT operations. It’s a dedicated storage solution designed for environments close to the cloud, giving customers quick, secure, and scalable access to public cloud providers through Equinix’s numerous data centers. This means businesses can efficiently connect to the cloud and manage their infrastructure with less hassle.
Ahead of this year’s Datacloud Global Congress 2024 where its CEO Giordano Albertazzi is set to join a keynote panel, Vertiv Holdings Co (NYSE: VRT) launched its new AI hub, featuring the industry’s first AI reference design portfolio for critical digital infrastructure.
The new Vertiv AI Hub offers a variety of helpful resources like white papers, industry research, and tools. It also includes information on power and cooling solutions for both new and existing facilities. Their new design library showcases flexible cooling and power systems that can handle both current and future computer chip needs, supporting anywhere from 10 to 140 kilowatts per rack.
“We are committed to providing deep knowledge, the broadest portfolio, and expert guidance to enable our customers to be among the first to deploy energy-efficient AI power and cooling infrastructure for current and future deployments,” said Albertazzi. “Our close partnerships with leading chipmakers and innovative data center operators make us uniquely qualified to help our customers and partners on their AI journey.”
Known for being a top company in storing paper documents and backup tapes, Iron Mountain Incorporated (NYSE: IRM) is expanding its data center network by opening a new data center in Toronto, Canada. The new facility is designed to support growth in its online backup services, Connected Backup and LiveVault, which provide automated backups for desktop PCs and specializes in server backups, respectively.
“In addition to opening the data center in Canada, Iron Mountain Digital is actively broadening its global data center presence and in the process of opening a series of data centers outside of the U.S. and Canada, to better support our customers wherever they do business,” said John Clancy, president of Iron Mountain Digital, the technology arm of Iron Mountain. “We’ve had a growing demand from our customers worldwide for data protection solutions and services.”
AI Data Cloud company Snowflake Inc. (NYSE: SNOW) recently released its financial results for Q1 2025, which included a 33% year-over-year growth in revenue, and a net revenue retention rate of 128%. The growth numbers came shortly ahead of Snowflake CEO Sridhar Ramaswamy’s scheduled fireside chat at the company’s 6th annual Snowflake Data Cloud Summit 2024 alongside NVIDIA Founder and CEO Jensen Huang.
“We finished our first quarter with strong performance across many of our key metrics,” said Ramaswamy in the Q1 2025 financials report. “Product revenue was up 34% year-over-year at nearly $790 million, while remaining performance obligations were $5.0 billion, up 46% year-over-year. Our core business is very strong. Our AI products, now generally available, are generating strong customer interest.”
As of the financial results release, Snowflake has 485 customers with trailing 12-month product revenue greater than $1 million, and 709 Forbes Global 2000 customers. Snowflake also announced its intent to acquire certain technology assets and hire key employees from TruEra, an AI observability platform. TruEra provides capabilities to evaluate and monitor large language model (LLM) applications and machine learning models in production.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.co.uk/news-releases/data-center-security-and-spending-skyrocket-amid-ai-boom-302160707.html
Embrace the Future with Computing Power! GIGABYTE AI PCs Lead You to Explore New Frontiers
TAIPEI, May 31, 2024 /PRNewswire/ — GIGABYTE is excited to present the “AI New Era” exhibition, showcasing how AI is transforming our world. This event explores AI-generated art, AI applications, and other immersive experiences that demonstrate the practical uses of AI PCs in everyday life.
Exhibition Themes
The “GIGABYTE AI New Era” exhibition features three thematic areas, each illustrating the diverse nature of AI:
AI Art: This area showcases dynamic images and interactive art created by international artists. Notable contributors include the Dimension + new media art team led by Escher Tsai (Taiwan) and Keith Lam (Hong Kong), Ygor Marotta from the VJ Suave studio in São Paulo, Brazil, and emerging Taiwanese artist Tim Wei. Attendees will embark on a sensory journey as these artists share their inner worlds and the collaborative process of integrating GIGABYTE AI PCs into their work. VS AI Street Battle: In collaboration with Hello World, this section challenges traditional art forms using the latest text-to-image AI applications. Utilizing GIGABYTE AI PCs’ powerful and stable computing capabilities, this area combines large-scale arcade fighting games with generative AI, creating a unique and creative battle system. AI Applications Featuring RTX -AI PCs: This area explores how AI enhances everyday life across various fields, including gaming, digital art, content creation, image processing, and productivity. Guided by GIGABYTE AI PCs, consumers can experience limitless AI applications, seamlessly integrating AI into their daily routines. Emmy-nominated filmmaker Hugh Hou (US) will curate the AI Use Case zone, showcasing the latest AI technology and providing a professional workflow for creating immersive videos. Additionally, GIGABYTE will collaborate with NVIDIA to showcase a series of advanced AI applications featuring GeForce RTX graphics cards.Invitation to All
GIGABYTE warmly welcomes technology enthusiasts and art connoisseurs to join this grand event and experience the revolution in technology and art brought by artificial intelligence. For more information about the event, please visit the official website: GIGABYTE AI 2024.
Join us in exploring the future of AI and its impact on our daily lives, and witness how GIGABYTE is leading the charge in integrating AI into the world of art and technology.
Photo – https://mma.prnewswire.com/media/2426946/GIGABYTE.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gigabyte-ai-new-era-humanity-x-art-x-technology-exhibition-302160686.html
-
Uncategorized6 days agoThrive with GBA | Greater Bay Area held conference in Paris to further ties with French companies
-
Uncategorized6 days ago
DEI MIA in new Meta AI advisory group
-
Uncategorized6 days ago
Why the National Spelling Bee is more vital than ever in the age of AI
-
Uncategorized6 days ago
Chinese state media warns AI could worsen job discrimination and break labour laws
-
Artificial Intelligence6 days agoPolyU research finds improving AI large language models helps better align with human brain activity
-
Artificial Intelligence6 days agoVivaTech 2024: a record-breaking event
-
Uncategorized6 days ago
E-commerce and Sustainability Drive Garment Packaging Machine Market Growth to USD 3.4 Billion by 2034, India Leads
-
Uncategorized6 days ago
Building better ethical standards for AI, for democracy
